Ivermectin and Fenbendazole Surge in US Prescriptions After Mel Gibson's Cancer Claims: What the Evidence Shows

The Conversation analyzes a spike in ivermectin and fenbendazole prescriptions in the United States following Mel Gibson's claims on the Joe Rogan Experience that the antiparasitics cured friends with stage 4 cancer. The article explains that current evidence comes mainly from cell and animal studies, not clinical trials in humans, and notes that early-stage trials are now underway to assess safety and potential efficacy. Fenbendazole is not approved for human use. Ivermectin shows some laboratory effects that could influence cancer biology, but translating these findings into a proven therapy remains unproven. Public self-dosing poses risks, underscoring the importance of evidence-based cancer treatments while trials proceed. Source: The Conversation

• Mel Gibson's claims can rapidly amplify public interest and online discussions.
• No conclusive human data yet; human trials are in early stages.
• Fenbendazole is not approved for human use; ivermectin's clinical value is unproven.
• Researchers call for large, well-designed clinical trials before any therapeutic claims.

Overview

The Conversation examines a notable rise in prescriptions for two antiparasitic drugs, ivermectin and fenbendazole, following a high-profile claim by actor Mel Gibson on the Joe Rogan Experience that these drugs cured friends of stage 4 cancer. The piece emphasizes that the current body of evidence is largely laboratory-based and that no robust clinical data demonstrate a cancer-curing effect in humans. It also highlights that human trials are now beginning to evaluate whether these drugs might have any real clinical benefit when used alongside conventional cancer therapies. Fenbendazole, unlike ivermectin, is not approved for human use, which adds another layer of caution to any considerations of off-label use.

Quote: "Most evidence for ivermectin and fenbendazole as cancer treatments comes from studies in cells or animals, not from clinical trials in patients." - The Conversation

What Gibson Claimed and How It Spread

The article recounts that Gibson claimed on a podcast that three friends with stage 4 cancer were cured after taking antiparasitic drugs, and that clips from the interview circulated rapidly on social media. This led to a surge in interest and inquiries about obtaining these drugs. While anecdotes can drive curiosity, the piece stresses that anecdotes do not replace rigorous clinical data.

Quote: "Without high-quality clinical evidence, these drugs should be considered experimental cancer treatments." - The Conversation

Laboratory Evidence vs. Clinical Reality

The piece outlines that ivermectin has been shown in laboratory settings to affect several biological processes linked to cancer growth and to interfere with pathways that help cancer cells survive. Other research explores whether ivermectin could enhance immune detection of tumors. However, laboratory findings do not automatically translate into effective clinical therapies, and the article notes that no studies to date have evaluated the effectiveness of these drugs in cancer patients in robust clinical trials. Some early-stage trials are underway to address this gap.

Quote: "Most evidence for ivermectin and fenbendazole as cancer treatments comes from studies in cells or animals, not from clinical trials in patients." - The Conversation

Fenbendazole: Animal Drug and Human Use

Fenbendazole is described as a benzimidazole antiparasitic primarily used in animals and not approved for human use. Laboratory studies show it can disrupt cancer cell glucose uptake, stress management, and structural integrity, potentially impairing tumor function. Public interest rose after a 2019 incident when a patient claimed recovery from lung cancer while using fenbendazole, but the article notes that this patient was also receiving experimental therapy and multiple other drugs. The piece stresses that these are early observations, not validated therapeutic results.

Ivermectin: Mechanisms, Evidence, and Cautions

The article reviews laboratory evidence that ivermectin could interfere with cancer cell survival pathways or boost immune-mediated tumor destruction. Yet it remains unclear whether these effects can translate into meaningful clinical benefit in humans, and there is a call for careful, controlled clinical research to determine potential risks and efficacy.

Why Scientists Remain Cautious

The core issue, according to the article, is the quality and translatability of evidence. Much of the existing data come from cellular or animal studies, with limited or no high-quality human trials. A previously reported major improvement in three cancer patients taking fenbendazole was retractéd due to concerns about data reliability. The article also addresses claims that the two drugs might work better together, noting that combination therapy has not been tested in humans.

Quote: "Combination therapy of the two antiparasitic drugs taken together have not been conducted." - The Conversation

Clinical Trials and Public Health Implications

Despite growing interest and some human trials in progress, the article emphasizes that ivermectin and fenbendazole should be considered experimental. Clinicians are advised to rely on evidence-based cancer treatments backed by clinical research. The article discusses the role of misinformation in shaping patient expectations and how this can impact health decisions and access to conventional therapies.

Conclusion and Next Steps

The Conversation concludes that while laboratory work provides intriguing hints, definitive answers require large, well-designed clinical trials to establish safety and efficacy. Until such data exist, public health messaging should emphasize evidence-based treatment options and careful patient counseling to avoid dangerous self-treatment and drug misuse.

Source: The Conversation